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There is evidence for increased levels of circulating reactive oxygen species (ROS) in diabetics, as indirectly  
inferred by the findings of increased lipid peroxidation and decreased antioxidant status. Direct measurements 
of intracellular generation of ROS using fluorescent dyes also demonstrate an association of oxidative s ress 
with diabetes. Although phenolic compounds attenuate oxidative stress-related tissue damage, there are con-
cerns over toxicity of synthetic phenolic antioxidants and this has considerably stimulated interest in investigat-
ing the role of natural phenolics in medicinal applications. Curcumin (the primary active principle in turmeric,
Curcuma longa Linn.) has been claimed to represent a potential antioxidant and antiinflammatory agent with 
phytonutrient and bioprotective properties. However there are lack of molecular studies t  demon rate its cellu-
lar action and potential molecular targets. In this study the antioxidant effect of curcumin as a function of 
changes in cellular ROS generation was tested. Our results clearly demonstrate that curcumin abolished both 
phorbol-12 myristate-13 acetate (PMA) and thapsigargin-induced ROS generation in cells from control and dia-
betic subjects. The pattern of these ROS inhibitory effects as a function of dose-dependency uggests that cur-
cumin mechanistically interferes with protein kinase C (PKC) and calcium regulation. Simultaneous measurements 
of ROS and Ca2+ influx suggest that a rise in cytosolic Ca2+ may be a trigger for increased ROS generation. We 
suggest that the antioxidant and antiangeogenic actions of curcumin, as a mechanism of inhibition of Ca2+ entry 
and PKC activity, should be further exploited to develop suitable and novel drugs for the treatment of diabetic 
retinopathy and other diabetic complications. 
[Balasubramanyam M, Koteswari A A, Kumar R S, Monickaraj S F, Maheswari J U and Mohan V 2003 Curcumin-induced inhibition of 
cellular reactive oxygen species generation: Novel therapeutic implictions; J . Biosci. 28 715–721] 
1. Introduction 
Increasing evidence in both experimental and clinic l 
studies suggests that oxidative stress plays a major role in 
the pathogenesis of diabetes mellitus (Mercuri et al 2000; 
Brownlee 2001; Rosen et al 2001; Bonnefont-Rousselot 
2002; Ceriello 2003). Free radicals are formed dispropor-
tionately in diabetes by glucose oxidation, non-enzymatic 
glycation of proteins, and the subsequent oxidative deg-
radation of glycated proteins. Abnormally high levels of 
free radicals and the simultaneous decline of antioxidant 
defense mechanisms can lead to damage of cellular  
organelles and enzymes, increased lipid peroxidation, and 
development of insulin resistance. Therefore, oxidative 
st ess is considered a common endpoint of chronic diseases 
like diabetes (Baynes 1991) and is often characterized by 
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an increase in the steady state concentration of reactive 
oxygen species (ROS), such as H2O2, lipid peroxides, 
superoxide and hypochlorous acid. Oxidative stress can 
modulate a wide variety of biological processes by coup-
ling signals at the cell surface with changes in gene ex-
pression, suggesting that multiple signalli g pathways are 
involved. Indeed, ROS may be defined as true second-
messenger molecules that regulate various signal trans-
duction cascades upstream of nuclear transcription factors, 
including modulation of Ca2+ signalling, protein kinase 
and protein phosphatase pathways (Sundaresan et al 
1995; Palmer and Paulson 1997). Therefore, it is impor-
tant to explore the relationship between free radicals, 
diabetes, and its complications, and to elucidate the mec-
hanisms by which increased oxidative stress accelerates 
the development of diabetic compli ations. These efforts 
will ultimately expand and increase our treatment options. 
 There is a need for screening of herbal medicines with 
special reference to diabetes and its complicati ns (Bala-
subramanyam and Mohan 2002). The significance of 
Curcuma longa Linn. (turmeric) in health and nutrition 
has changed considerably since the discovery of the anti-
oxidant properties of naturally occurring phenolic com-
pounds. The dried rhizome of C. longa (used as a spice, 
food preservative and a colouring agent) is a rich source 
of beneficial phenolic compounds; the curcuminoids (Sri-
nivasan 1953). Curcuminoids are a group of phenolics 
present in turmeric. These curcuminoids are chemically 
related to its principal ingredient; the curcumin. Three 
main curcuminoids were isolated from turmeric: namely; 
curcumin (C), demethoxycurcumin (DMC) and bisdemeth-
oxycurcumin (BDMC). In this study we have tested the 
antioxidant effect of curcumin as a function of changes in 
cellular ROS generation and explored its novel mecha-
nisms of protection against oxida ive stress. 
2. Materials and methods 
2.1 Study subjects 
All study subjects were recruited from M V Diabetes 
Specialities Centre (MVDSC) at Gopalapuram, Chennai. 
Additionally, healthy volunteers were also recruited for 
blood sampling for the standardization of various metho-
dologies related to cellular approaches. Statistical data 
analysis was performed using PC-compatible SPSS pack-
age. 
2.2 Lymphocyte isolation 
Freshly collected blood was carefully layered on top of 
Histopaque (1077) or Lymphoprep density gradient solu-
tion and centrifuged at 1600 rpm for 30 min. The buffy 
coat interface that represents lymphocytes was aspirated 
and suspended in 1 ml HEPES buffered saline (HBS, 
pH 7×4) containing 140 mM NaCl, 5 mM KCl, 10 mM 
HEPES, 10 mM glucose, 1 mM CaCl2 and 1 mM MgCl2. 
Curcumin, thapsigargin, dicholorofluorescein diacetate, 
Fura2-AM and phorbol-12 myrsitate-13 acetate (PMA) 
were obtained from Sigma-Aldrich Co., USA. All other re-
agents used were of analytical grade. 
 
2.3 Determination of intracellular ROS production 
To asure intracellular ROS production, cells were 
loaded with 10 mM dichlorofluorescein diacetate (DCFH-
DA) for 45 min. ROS levels were measured (using 
Fluoromax-3 spectrofluorimeter with an excitation set at 
485 nm and emission at 530 nm) as a change in the fluo-
rescence because of the conversion of non-fluorescent 
dichlorofluorescein diacetate to the highly fluorescent 
compound 2¢,7¢-dichlorofluorescein (DCF) in the cells. 
Aliquots of cell suspension (100ml) were incubated for 
10 min with curcumin and resuspended in HBS prior to 
each experiment. This potentially eliminated the interfer-
ence of curcumin in fluorescence assays. 
2.4 Measurement of Ca2+ influx 
Ly phocyte suspension was incubated with 5 mM Fura-2 
AM for a minimum of 30 min at 37°C and delivered as 
100 ml aliquots. Prior to each experiment, cells were cen-
trifuged for 5–10 s at room temperature, resuspended in 
100 ml of HBS, and injected into cuvettes containing 3 ml 
of assay buffer. Ca2+ influx was measured using a metho-
dology of Mn2+ quenching of intracellular fura (Balasub-
ramanyam et al 1993). Here, Mn2+ is used as a surrogate 
marker of measuring Ca2+ entry. When measured at an 
isobestic wavelength of 360 nm, the Mn2+ quenching of 
intracellular fura is a relative measurement of Ca2+ entry 
into the cells. 
3. Results 
 
Curcumin-induced cellular changes were studied using 
two agents viz., thapsigargin (Tg) and PMA which spe-
cifically interfere with calcium and protein kinase C 
(PKC) metabolism, respectively, and increase cellular 
ROS production. Tg is a pharmacological specific inhibitor 
of sarcoplasmic endoplasmic reticular calcium (SERCA). 
ATPases and cells treated with Tg exhibit depletion of 
intracellular Ca2+ stores and subsequent rise in cytosolic 
Ca2+, as a function of store-op rated Ca2+ influx (Thastrup 
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et al 1990; Balasubramanyam et al 1993). PMA is a 
common activator of cellular PKC isozymes (Ohno and 
Nishizuka 2002). Figure 1 shows the Tg-induced ROS gene-
ration in cells from control and dibetic subjects, with a 
general trend of increased ROS in diabetic p tients. In 
cells pretreated with curcumin (100 mM), there was a 
total absence of Tg-induced ROS generation. The extent 
of curcumin inhibition of Tg-induced ROS generation 
was almost same in cells from control (88% ± 4×5) and 
diabetic (92% ± 1×7) subjects. When lymphocytes were 
treated with PMA – a PKC activator – PMA induced increa-
sed levels of ROS generation (figure 2). In general, 
PMA-induced ROS generation was less in cells from dia-
betes patients compared to control subjects. However, the 
extent of curcumin inhibition of PMA-induced ROS gen-
eration was almost the same in cells from control 
(91% ± 3×6) and diabetic (88% ± 4×34) subjects. To prove 
that the effect of curcumin was not non-specific but 
rather a mechanistic biological phenomenon, dose-d pen-
dent effects of curcumin were tested on both Tg-induced 
and PMA-induced ROS generation. Curcumin dose-depen-
dently (0×1 mM to 100 mM) inhibited PMA-induced cyto-
solic ROS levels (figure 3). Similar inhibitory effects of 
curcumin (0×3 mM to 100 mM) were also observed on Tg-
induced ROS generation (data not shown). These results 
demonstrate specific biological effects of curcumin on 
important messenger molecules, such as cytosolic calcium 
nd PKC. 
 Earlier studies indicated that Tg-induced cellular Ca2+ 
entry was higher in cells from diabetes patients (Bala-
subramanyam et al 2001), and an increase in cytosolic 
Ca2+ via store-operated Ca2+ entry is a prerequisite for 
increased intracellular ROS generation (Balasubramanyam 
et al 2002). If there is an existence of a cross-talk signal-
ling of increased ROS and cytosolic calcium, it should be 
possible to demonstrate in an experiment where simulta-
neously ROS and Ca2+ entry are measured. As shown in 
figu e 4, Mn quenching of intracellular fura is a reliable 
measure of Ca2+ entering into the cells (dotte  lines) and 
DCF-fluorescence is a reliable measure of intracellular 
ROS generation, both events initiated by Tg. This metho-
dology clearly indicates that an increase in Ca2+ rise  
in the cell is a trigger for increased ROS generation.  
Interestingly, curcumin inhibits both Tg-induced Ca2+ 
entry and ROS generation, suggesting that Ca2+ entry 
inhibition might be one of the mechanisms by which  
curcumin exerts its antioxidant effect and inhibits ROS 
generation. 
 
Figure 1. Curcumin inhibition of Tg-induced ROS generation in cells from control (A) and type 2 diabetes 
subjects (B). Freshly isolated lymphocytes were resusp nded in HBS buffer and loaded with 10 mM DCF for 
45 min. At time ‘0’ thapsigargin (100 nM) was added and i crease in DCF fluorescence was monitored for 
1000 s, with and without curcumin (100 mM). Insets indicate percent inhibition of ROS generation by curcumin. 
Each bar diagram represents cumulative data obtained from 6 to 10 separate experiments. 
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Figure 2. Curcumin inhibition of PMA-induced ROS generation in cells from control (A) and type 2 diabetes 
subjects (B). Experimental maneuvers were same as in figure 1. 
 
 
Figure 3. Curcumin dose-d pendently inhibits PMA-induced intracellular ROS generation. Increases in DCF 
fluorescence after the addition of PMA were monitored in the absence and presence (1mM to 100 mM) of cur-
cumin. Representative traces of 4 separate dose-dependency experiments. 
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4. Discussion 
Earlier studies have shown that curcumin can affect a 
number of cellular processes including activation of apop-
tosis in Jurkat T cells (Piwocka et l 1999), inhibition of 
platelet aggregation (Shah et al 1999; Srivastava et al 
1995), and inhibition of inflammatory cytokine produc-
tion in macrophages (Abe et al 1999). Curcumin has also 
been shown to affect the activity of a number of key en-
zymes such as cyclooxygenase (Zhanget al 1999), PKC 
(Liu et al 1993), protein tyrosine kinases (Chen and 
Huang 1998) and a Ca2+-dependent endonuclease (Chen
et al 1996). Many of these processes/enzymes were known 
to be regulated by Ca2+. Cytosolic calcium is tightly con-
trolled. The sarco/endoplasmic reticulum Ca2+ ATPase 
(SERCA) is one of the major mechanisms by which the 
low levels of cytosolic calcium (~ 100 nM) are main-
tained within cells. Interestingly, it has been shown that 
all subtypes of SERCA are inhibited to a similar degree 
by curcumin (Bilmen t al 2001). In our study, curcumin 
inhibits Tg-induced ROS production and Ca2+ entry. The 
likely mechanisms are: (i) curcumin apart from its effects 
on SERCA may also inhibit inositol-triphosphate(IP3)-
sensitive Ca2+ channel (Dyer t al 2002) and thereby 
break the coupling of IP3-sensitive Ca2+ store and Ca2+ 
entry; and (ii) curcumin may inhibit cytosolic signals 
(enzymes or other signalling molecules) that are respon-
sible for Ca2+ entry into the cells. 
 
Figure 4. Methodology for simultaneous measurement of ROS generation and Ca2+ influx. Cells were 
co-loaded with both DCF and Fura and changes in respective fluorescence intensities were monitored 
using multiwavelength parameters in a Fluoromax-3 spectrofluorimeter. Solid lines represent increases in 
Tg-induced ROS generation (A) and its inhibitio  by curcumin (B). Dotted lines represent Tg-induced 
Mn2+ quenching (C) of intracellular fura (a surrogate measure of Ca2+ influx) and its inhibition by cur-
cumin (D). Representative traces of 4 separate experiments. Inset: Traces (C) and (D) were separately 
illustrated to show the extent of Tg-induced Ca2+ influx and its inhibition by curcumin. 
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 Curcumin inhibition of PMA-induced ROS generation 
suggests that curcumin has an inhibitory action on PKC 
activity. It is now recognized that low levels of oxidants 
can modify cell-signalling proteins and that these modifi-
cations have functional consequences (Lee et al 1989). 
For example, PKC is a logical candidate for redox modi-
fication by oxidants and antioxidants that may in part 
determine their cancer-promoting and anticancer activi-
ties, respectively. PKC contains unique structural features 
that are susceptible to oxidative modification. The N-termi-
nal regulatory domain contains zinc-binding, cysteine-
rich motifs that are readily oxidized by peroxide. When 
oxidized, the auto inhibitory function of the regulatory 
domain is compromised and, consequently, cellular PKC 
activity is stimulated. The C-terminal catalytic domain con-
tains several reactive cysteines that are targets for various 
chemopreventive antioxidants (such as selenocompounds), 
polyphenolic agents (such as curcumin), and vitamin E ana-
logues (Gopalakrishna and Jaken 2000). Modification of 
these cysteines decreases cellular PKC activity. Thus the 
two domains of PKC respond differently to two different 
types of agents. Oxidants selectively react with the regu-
latory domain, stimulate cellular PKC, and act as a signal 
for tumour promotion and cell growth. In contrast, anti-
oxidant chemo preventive agents reac with the catalytic 
domain, inhibit cellular PKC activity, and, thus, interfere 
with the PKC-overactivation-driven pathological processes. 
 Curcumin inhibition of PKC may impose several thera-
peutic implications in diabetes, particularly in case of 
diabetic retinopathy. Increased PKC activation has been 
demonstrated in experimental diabetic retinopathy studies 
(Kowluru 2001) and several PKC inhibitors (PKCbII) are 
being tested for their efficacy and safety in clinical trials 
(Frank 2002). Specifically, in diabetic retinopathy, both 
the genesis and the advanced stage of proliferative dia-
betic retinopathy (PDR) have been hypothesized to be a 
result of increased oxidative species (Armstrong et al 
1998) or to be associated with ischemia-perfusion injury 
at the boundaries of perfused and nonperfused retina, 
which leads to both increased oxidative species and neo-
vascularization. Since curcumin is also an angiogenesis 
inhibitor and inhibits multistep progression of angio-
genesis in vitro and in vivo, one cannot underestimate its 
therapeutic potentials. It appears that the pleiotropic 
effects of curcumin are at least partly due to inhibition of 
the transcription factors NF-kappa B and AP-1 (Bierhaus 
et al 1997). Okamoto et al (2002) reported that curcmin 
prevents the AGE-induced increase in NF-kB and AP-1 
activity, vascular endothelial growth-factor (VEGF) 
mRNA up-regulation and the resultant increase in DNA 
synthesis in microvascular endothelial cells. Any drug 
with multiple actions, such as antioxidant and anti-
angiogenic eff cts, is an ideal formulation in the treatment 
of diabetic retinopathy. 
 Our results demonstrate that antioxidant effects of cur-
cumin involve, among other mechanisms, the inhibition 
of Ca2+ influx and PKC. This information extends the known 
cellular actions of curcumin to potentially multiple thera-
peutic targets. Pharmacologically, curcumin is reported 
as safe (Aggarwal et al 2003). A phase-one human trial 
with 25 subjects using up to 8000 mg of curcumin per 
day for 3 months found no toxicity from curcumin 
(Cheng et al 2001). Five other human trials using 1125–
2500 mg of curcumin per day also showed no toxicity 
(Chainani-Wu 2003). Xu et al (2003) reported that cur-
cumi inhibited the proliferation of activated hepatic stel-
late cells and this thas been mediated by curcumin in-
duction of the gene expression of PPARg and PPARg 
activation. The PPARg agonists, thioaz lidenediones (which 
are primarily antidiabetic agents) are claimed to offer 
multiple therapeutic benefits via their beneficial vascular 
nd anti-inflammatory effects (Martens et al 2002). In 
his context, curcumin on further scientific validation 
appears to have multiple potential in the treatment regimen 
of diabetes and its complications, which constitutes a col-
lection of metabolic, vascular and inflammatory defects. 
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